// Physician-monitored weight management

Medical Weight Management (Semaglutide)

Semaglutide (compounded, prescription)

Physician-supervised weight management using semaglutide, a GLP-1 receptor agonist. Prescribed and monitored within a structured program — initial medical evaluation, monthly check-ins, blood work, and a frank conversation about long-term goals.

What it is

Semaglutide is a GLP-1 receptor agonist — a class of medications originally developed for type 2 diabetes that have been shown to support meaningful weight loss in patients who meet specific criteria. When prescribed and monitored within a structured medical program, semaglutide reduces appetite, slows gastric emptying, and supports caloric restriction without the white-knuckle effort of willpower alone.

How we approach it

This is a medical program, not a weight-loss product. The first visit is a real medical evaluation — history, BMI, prior weight history, current medications, contraindications, blood work. We discuss your goals candidly, including whether semaglutide is the right tool for you.

Monthly follow-up is standard. Dose titration is gradual to mitigate GI side effects. Nutrition, hydration, and movement habits are part of the conversation at every visit — the medication is a tool that works best paired with the habits.

The program is open to patients who meet criteria and who can commit to the monthly cadence.

What to expect

After medical clearance, the medication is started at a low dose and titrated upward over weeks. Early side effects (nausea most commonly) typically resolve within the first month and respond to dose adjustment.

Weight changes are gradual — meaningful loss over months, not weeks. Follow-up labs are scheduled per the program protocol.

Candidacy

Eligibility is determined at the initial medical visit and includes BMI criteria, contraindication screening, and the candor of the conversation about goals. Not appropriate during pregnancy, breastfeeding, or for patients with a personal or family history of medullary thyroid carcinoma or MEN-2. History of pancreatitis requires clearance.

If semaglutide is not appropriate for you, the clinician will say so and discuss alternatives.

Indicated for

  • Adults with a BMI qualifying for medical weight management
  • Patients who can commit to monthly follow-up and program structure
  • Patients ready to integrate nutrition, hydration, and movement changes alongside the medication

Not a candidate if

  • Pregnant or nursing patients, or patients planning pregnancy in the near term
  • Personal or family history of medullary thyroid carcinoma or MEN-2
  • History of pancreatitis without medical clearance
  • Patients seeking the medication outside a monitored program

Before your visit

  • Common early side effects: nausea, occasional vomiting, constipation, fatigue. Most resolve in the first weeks; titration mitigates.
  • The medication is one tool. Sustainable outcomes pair the medication with nutrition, hydration, and movement habits.
  • Cost and insurance coverage vary; the program is structured for adherence and follow-up regardless of source.

Begin with the consultation.

Every plan is drawn before it is performed. The team trains under Dr. Brown.